These compounds may interact with:
5-hydroxytryptamine receptor 3E
Potentially involved in: carcinoma; irritable bowel syndrome; dyspepsia; diarrhea; schizophrenia; intubation of gastrointestinal tract; gastroesophageal reflux disease; chemotherapy-induced nausea and vomiting; diabetic gastroparesis; gastrointestinal radiography adjunct; prevention of post-operative nausea and vomiting
Disease data sourced from Pharos.